Source: NICE

The Skinny: Guideline to improve the diagnosis and management of chronic open angle glaucoma (COAG) and ocular hypertension (OHT).

Documents For healthcare professionals:

• CG85 Glaucoma: NICE guideline (37p, 247.73 Kb )
• CG85 Glaucoma: NICE guideline (MS Word format) (37p, 635.5 Kb)
• CG85 Glaucoma: full guideline (261p, 5.28 Mb)
• CG85 Glaucoma: full guideline appendices (281p, 6.64 Mb)
• CG85 Glaucoma: quick reference guide (16p, 477.46 Kb)

Documents For patients, carers and the public:

• CG85 Glaucoma: understanding NICE guidance (12p, 597.32 Kb)
• CG85 Glaucoma: understanding NICE guidance (large print) (20p, 88.95 Kb)

Date of publication: April 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Applies to children younger than 5 years who present to a healthcare professional for advice in any setting. It covers diagnosis, assessment of dehydration, fluid management, nutritional management and the role of antibiotics and other therapies. It provides recommendations on the advice to be given to parents and carers, and also considers when care should be escalated – from home management through to hospital admission.

The guideline will assume that prescribers will use a drug’s summary of product characteristics to inform their decisions for individual patients.

Documents For healthcare professionals:

• CG84 Diarrhoea and vomiting in children under 5: NICE guideline (MS Word format) (33p, 1.81 Mb)
• CG84 Diarrhoea and vomiting in children under 5: full guideline (200p, 3.19 Mb)
• CG84 Diarrhoea and vomiting in children under 5: quick reference guide (16p, 77.38 Kb)

Documents For patients, carers and the public:

• CG84 Diarrhoea and vomiting in children under 5: understanding NICE guidance (8p, 409.43 Kb)
• CG84 Diarrhoea and vomiting in children under 5: understanding NICE guidance (MS Word format) (8p, 233 Kb)

Background Information:

• CG84 Diarrhoea and vomiting in children under 5: evidence tables (152p, 1.2 Mb)
• CG84 Diarrhoea and vomiting in children under 5: search strategies (173p, 944.26 Kb)
• NICE issues guidance to help assess and treat children with gastroenteritis (4p)

Implementing the guidance:

• Diarrhoea and vomiting in children under 5: costing statement (3p, 34.17 Kb)

Date of publication: April 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: This guidance is about when rivaroxaban should be used to reduce the risk of thromboembolism in adults who have surgery to replace their hip or knee joints in the NHS in England and Wales. It explains guidance (advice) from NICE (the National Institute for Health and Clinical Excellence). It does not cover using rivaroxaban to reduce the risk of venous thromboembolism in adults who have had other types of surgery.

Documents For healthcare professionals:

• TA170 Venous thromboembolism – rivaroxaban: guidance (23p, 190.93 Kb)
• TA170 Venous thromboembolism – rivaroxaban: guidance (MS Word format) (23p, 553.5 Kb)
• TA170 Venous thromboembolism – rivaroxaban: quick ref guide(2p, 42.73 Kb)

Documents For patients, carers and the public:

• TA170 Venous thromboembolism – rivaroxaban: understanding NICE guidance (4p, 72.27 Kb)
• TA170 Venous thromboembolism – rivaroxaban: understanding NICE guidance (MS Word format) (4p, 553.5 Kb)

Implementing the guidance:

• Venous thromboembolism – rivaroxaban: costing statement (3p, 34.59 Kb)
• Venous thromboembolism – rivaroxaban: audit support (4p, 163 Kb)

Date of publication: April 2009

Publication type: Technology Appraisal

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Children are sometimes born with defects of the hip joint and upper thigh bone, called proximal femoral focal deficiency, often abbreviated to PFFD. Surgical treatment, aiming to produce as functional a leg as possible, may be appropriate. This may also involve a corrective operation on the hip joint (sometimes referred to as the ‘superhip’ procedure). The initial operation may be combined with other surgery to lengthen the leg and treat other problems such as poor knee function at the same time or at a later date.

Full guidance to the NHS in England, Wales, Scotland and Northern Ireland on ex-vivo hepatic resection and reimplantation for liver cancer.

Documents:

• IPG297 Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD): guidance (2p, 74.35 Kb)
• IPG297 Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD): understanding NICE guidance (4p, 50.13 Kb)
• IPG297 Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD): understanding NICE guidance (MS Word format) (4p, 406 Kb)
• Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD)(interventional procedures overview) (16p, 92 Kb)
• Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD): audit support (12p, 409.5 Kb)
• IPG297 Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD): consultation comments (4p, 33.93 Kb)
• Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD) (interventional procedures consultation) (web page)

Date of publication: April 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: This procedure involves removing the liver from the body, cutting away the diseased tissue, and reimplanting the remaining tumour-free liver into the patient.

The liver may be affected by cancer, either spreading from other parts of the body or developing from within the organ. In some patients, the tumour may develop in parts of the liver that are dangerous or impossible to treat with surgery, for example, when the tumour is very close to major veins that connect to the liver.

Full guidance to the NHS in England, Wales, Scotland and Northern Ireland on ex-vivo hepatic resection and reimplantation for liver cancer.

Documents:

• IPG 298 Ex-vivo hepatic resection and reimplantation for liver cancer: guidance (2p, 73.74 Kb)
• PG 298 Ex-vivo hepatic resection and reimplantation for liver cancer: understanding NICE guidance (4p, 49.96 Kb)
• IPG 298 Ex-vivo hepatic resection and reimplantation for liver cancer: understanding NICE guidance (MS Word format) (4p, 406.5 Kb)
• Ex-vivo hepatic resection and reimplantation for liver cancer (interventional procedures overview)(20p, 115.22 Kb)
• Ex-vivo hepatic resection and reimplantation for liver cancer (interventional procedures consultation (web page)

Date of publication: April 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Treatment for early breast cancer usually involves surgery to remove all or part of the breast. In this keyhole procedure, part or all of the breast tissue is removed using special instruments inserted through small skin incisions. The skin envelope of the breast and nipple are left intact, ready for an implant that can be inserted during the same operation.

Full guidance to the NHS in England, Wales, Scotland and Northern Ireland on ex-vivo hepatic resection and reimplantation for liver cancer.

Documents:

• IPG296 Endoscopic mastectomy and endoscopic wide local excision for breast cancer: guidance (2p,52.69 Kb )
• IPG296 Endoscopic mastectomy and endoscopic wide local excision for breast cancer: understanding NICE guidance (4p, 48.43 Kb)
• IPG296 Endoscopic mastectomy and endoscopic wide local excision for breast cancer: understanding NICE guidance (MS Word format)(4p, 405.5 Kb)
• Endoscopic mastectomy and endoscopic wide local excision for breast cancer: consultation comments (4p, 29.7 Kb)
• Endoscopic mastectomy and endoscopic wide local excision for breast cancer: interventional procedures overview (28p, 187.4 Kb)
• Endoscopic mastectomy and endoscopic wide local excision for breast cancer: interventional procedures consultation (web page)

Date of publication: April 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:Rheumatoid arthritis is a long-term disease in which joints in the body become inflamed, causing pain, swelling and stiffness. It is known as an ‘autoimmune disease’ because it is caused when the body’s immune system, which normally fights infection, starts to attack healthy joints. Rheumatoid arthritis can be very painful and affect a person’s ability to carry out everyday tasks. It is not known why rheumatoid arthritis develops, and there is no cure. Understanding of the disease has improved, and there are now effective treatments that can help ease the pain and symptoms, and slow down the disease. It is very important that treatment is started early to minimise damage to joints.

This guidance updates and replaces the following technology appraisals:

• TA27 Osteoarthritis and rheumatoid arthritis – cox II inhibitors (partially updated by CG59)
• TA72 Rheumatoid arthritis – anakinra

Documents For healthcare professionals:

• CG79 Rheumatoid arthritis: NICE guideline (35p, 258.97 Kb)
• CG79 Rheumatoid arthritis: NICE guideline (MS Word format) (35p, 624 Kb)
• CG79 Rheumatoid arthritis: full guideline (234p, 3.83 Mb)
• CG79 Rheumatoid arthritis: full guideline appendices (41p, 831.88 Kb)
• CG79 Rheumatoid arthritis: evidence tables (591p, 2.98 Mb)
• CG79 Rheumatoid arthritis: algorithm (jpg, 1.03 Mb)
• CG79 Rheumatoid arthritis: quick reference guide (12p, 134.4 Kb)

Documents For patients, carers and the public:

• CG79 Rheumatoid arthritis: understanding NICE guidance (12p, 166.65 Kb)
• CG79 Rheumatoid arthritis: understanding NICE guidance (MS Word format)(12p, 514.5 Kb)

Implementing Guidance:

• Rheumatoid arthritis: costing template (Excel, 841 Kb)
• Rheumatoid arthritis: costing report (26p, 183.94 Kb)
  
• Rheumatoid arthritis: slide set (powerpoint, 673.5 Kb)

Date of publication: February 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: NICE guideine on the care of:

• adults who, as a result of critical illness, have stayed in critical care and need rehabilitation.

It doesn’t look at the care of:

• adults who are having treatment for symptoms and pain in the final stages of a terminal illness
• adults whose rehabilitation needs are already routinely assessed and delivered as part of their care, for example, patients who have brief stays in critical care units for immediate postoperative care after major elective surgery, and patients with conditions for which published guidelines already exist – such as head injury, heart attack and stroke.

Documents For healthcare professionals:

• CG83 Critical illness rehabilitation: NICE guideline (91p, 496.21 Kb)
• CG83 Critical illness rehabilitation: NICE guideline (MS Word format) (91p, 1.34 Mb)
• CG83 Critical illness rehabilitation: appendices (100p, 499.86 Kb)
• CG83 Critical illness rehabilitation: quick reference guide (2p, 115.05 Kb)
• CG83 Critical illness rehabilitation: quick reference guide (printable version) (6p, 63.53 Kb)

Documents For patients, carers and the public:

• CG83 Critical illness rehabilitation: understanding NICE guideline (12p, 84.56 Kb)
• CG83 Critical illness rehabilitation: understanding NICE guidance (MS Word format) (12p, 505 Kb)

Implementing the Guidance:

• Critical illness rehabilitation: Supporting statement from national stakeholders (2p, 92.25 Kb)
• Critical illness rehabilitation: slide set (web page)

Date of publication: March 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Updates and replaces:

• Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. NICE clinical guideline 1 (2002)
• Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE technology appraisal guidance 43 (2002)

Documents For healthcare professionals:

• CG82 Schizophrenia (update): NICE guideline (41p, 256.26 Kb)
• CG82 Schizophrenia (update): NICE guideline (MS Word format) (41p, 605 Kb)
• CG82 Schizophrenia (update): full guideline (399p, 3.16 Mb)
• CG82 Schizophrenia (update): full guideline – clinical evidence summary tables (194p, 2.54 Mb)
• CG82 Schizophrenia (update): full guideline appendix 14 (90p, 599.94 Kb)
• CG82 Schizophrenia (update): full guideline appendix 15 (781p, 2.91 Mb)
• CG82 Schizophrenia (update): full guideline appendix 16a (11p, 76.44 Kb)
• CG82 Schizophrenia (update): full guideline appendix 16b (60p, 260.47 Kb)
• CG82 Schizophrenia (update): full guideline appendix 16c (613p, 2.14 Mb)
• CG82 Schizophrenia (update): full guideline appendix 16d (707p, 2.71 Mb)
• CG82 Schizophrenia (update): full guideline appendix 17 (16p, 176.19 Kb)
• CG82 Schizophrenia (update): quick reference guide (16p, 327.65 Kb)

Documents For patients, carers and the public:

• CG82 Schizophrenia (update): understanding NICE guidance (20p, 121.04 Kb)
• CG82 Schizophrenia (update): understanding NICE guidance (MS Word format) (20p, 551.5 Kb)

Implementing the Guidance:

• Schizophrenia (update): costing statement (8p, 92.79 Kb)
• Schizophrenia (update): costing tool (Excel, 1.63 Mb)
• Schizophrenia (update): slide set (powerpoint presentation)

Date of publication: March 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:

This guideline covers:

• some of the tests and treatments that patients with early and locally advanced breast cancer should be offered, in particular:
  – reducing the amount of surgery under your arm
  – breast reconstruction when breast conservation is not possible
  – chemotherapy and endocrine treatments
  – biological treatments.

It does not specifically look at:

• the care of patients with advanced breast cancer or those with rare or non-cancerous tumours of the breast
• the care of people who do not have breast cancer themselves but have a family history of the disease.

This guideline updates the following technology appraisals:

• TA107 Breast cancer (early) – trastuzumab (published August 2006)
• TA108 Breast cancer (early) – paclitaxel (published September 2006)
• TA109 Breast cancer (early) – docetaxel (published September 2006).

Documents For healthcare professionals:

• CG80 Early and locally advanced breast cancer: NICE guideline (37p, 233.95 Kb)
• CG80 Early and locally advanced breast cancer: NICE guideline (MS Word format) (37p, 616 Kb)
• CG80 Early and locally advanced breast cancer: full guideline (193p, 4.28 Mb)
• CG80 Early and locally advanced breast cancer: quick reference guide (20p, 183.2 Kb)

Documents For patients, carers and the public:

• CG80 Early and locally advanced breast cancer: understanding NICE guidance (20p, 179.3 Kb)
• CG80 Early and locally advanced breast cancer: understanding NICE guidance (MS Word format) (20p, 568.5 Kb)

Implementing the Guidance:

• Early and locally advanced breast cancer: costing template (Excel Spreadsheet, 1.33 Mb)
• Early and locally advanced breast cancer: costing report (34p, 250.6 Kb)
• Early and locally advanced breast cancer: slide set (Powerpoint Presentation 675 Kb)

Date of publication: February 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:  Guidance about enabling patients to make informed choices by involving and supporting them in decisions about prescribed medicines. It explains guidance (advice) from NICE (the National Institute for Health and Clinical Excellence) to the NHS in England and Wales.

Documents For healthcare professionals:

• CG76 Medicines adherence: NICE guideline (30p, 204.99)
• CG76 Medicines adherence: NICE guideline (MS Word format) (30p, 659.5 Kb)
• CG76 Medicines adherence: full guideline (364p, 1.27 Mb)
• CG76 Medicines adherence: quick reference guide (12p, 348.46 Kb)
• CG76 Medicines adherence: full guideline, appendix A (9p, 100.32 Kb)
• CG76 Medicines adherence: full guideline, appendix B (34p, 241.15 Kb)
• CG76 Medicines adherence: full guideline, appendix C (242p, 446.68 Kb)
• CG76 Medicines adherence: full guideline, appendix D (9p, 21.54 Kb)
• CG76 Medicines adherence: full guideline, appendix E (11p, 22.51 Kb)

Documents For patients, carers and the public:

• CG76 Medicines adherence: understanding NICE guidance (MS Word format) (12p, 517 Kb)
• CG76 Medicines adherence: understanding NICE guidance (12p, 202.5 Kb)

Date of publication: January 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Updates and replaces NICE technology appraisal guidance 62 (published May 2003), 54 (published December 2002) and 30 (published September 2001).

The advice in the NICE guideline describes the tests, treatment, care and support that patients with advanced breast cancer should be offered.

It does not specifically describe the care of patients with early breast cancer or those with rare or non-cancerous tumours of the breast.

Documents For healthcare professionals:

• CG81 Advanced breast cancer: NICE guideline (26p, 222.55 Kb)
• CG81 Advanced breast cancer: NICE guideline (MS Word format) (26p, 586 Kb)
• CG81 Advanced breast cancer: full guideline (122p, 3.03 Mb)
• CG81 Advanced breast cancer: quick reference guide (14p, 327.18 Kb)

Documents For patients, carers and the public:

• CG81 Advanced breast cancer: understanding NICE guidance (16p, 155.93 Kb)
• CG81 Advanced breast cancer: understanding NICE guidance (MS Word format) (16p, 155.93 Kb)
  

Date of publication: February 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Covers the care, treatment and support that people with borderline personality disorder should be offered.

Documents For healthcare professionals:

• CG78 Borderline personality disorder (BPD): NICE guideline, (41p., 270.06 Kb)
• CG78 Borderline personality disorder (BPD): NICE guideline (MS Word format), (41p, ,642.5 Kb)
• CG78 Borderline personality disorder (BPD): full guideline, interim proof copy, (495p., 2.94 Mb)
• CG78 Borderline personality disorder (BPD): quick reference guide, (20p, 502.26 Kb)

Documents For patients, carers and the public:

• CG78 Borderline personality disorder (BPD): understanding NICE guidance, (16p, 287.69 Kb)
• CG78 Borderline personality disorder (BPD): understanding NICE guidance (16p, 287.69 Kb)

Date of publication: January 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:  Antisocial personality disorder is is defiend as a condition that affects a person’s thoughts, emotions and behaviour. Antisocial means behaving in a way that is disruptive to, and may be harmful to, other people.

This guideline covers:

• The care, treatment and support that people with antisocial personality disorder and their families or carers should be offered
• The care and treatment that children with conduct problems and their families or carers should be offered.

It exclude:

• Treatments not normally available in the NHS or prison health services.

Documents For healthcare professionals:

• CG77 Antisocial personality disorder: NICE guideline (48p, 273.77 Kb)
• CG77 Antisocial personality disorder: NICE guideline (MS Word format), (48p, 675 Kb)
• CG77 Antisocial personality disorder: full guideline, interim proof copy (393p, 1.83 Mb)
• CG77 Antisocial personality disorder: quick reference guide, (23p, 307.05 Kb)

Documents For patients, carers and the public:

• CG77 Antisocial personality disorder: understanding NICE guidance, (12p, 244.83 Kb)
• CG77 Antisocial personality disorder: understanding NICE guidance (MS Word format), (12p, 161.5 Kb)

Date of publication: January 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: NICE has been appraising the use of bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma.

Sunitinib is recommended as a possible first drug treatment for people with advanced and/or metastatic renal cell carcinoma if:

• immunotherapy (for example, interferon alfa) would be suitable for them and
• they are mobile and can do light housework or office work.

When assessing people with disabilities, healthcare professionals should bear in mind that a person’s disability might also affect their level of physical activity. They should make adjustments for this.

Specialists should not stop prescribing sunitinib for people who were already taking it when the guidance was issued. These people should be able to carry on taking sunitinib until they and their specialist decide that it is the right time to stop treatment.

Documents For healthcare professionals:

• TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: guidance (32p, 252.88 Kb)
• TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: guidance (MS Word format) (32p, 598.5 Kb)
• TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: quick reference guide (2p, 64.34 Kb)

Documents For patients, carers and the public:

• TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: understanding NICE guidance (4p, 93.22 Kb)
• TA169 Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: understanding NICE guidance (MS Word format) (4p, 504.5 Kb)

Implementing the guidance:

• Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: audit support (MS Word format) (5p, 174.5 Kb)
• Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: costing template (Excel, 1012 Kb)

Date of publication: March 2009

Publication type: Technology Appraisal

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Recommendations about oseltamivir and zanamivir should not reduce efforts to give vaccination (also called the flu jab) to people for whom it is recommended in national guidelines.

The guidance does not cover widespread epidemics.

Oseltamivir and zanamivir are recommended as possible treatments for people with flu if all of the following apply:

• the person is in an ‘at-risk’ group
• the person has a ‘flu-like illness’ and can start treatment within 48 hours (36 hours for zanamivir treatment in children) of the first sign of symptoms.
• the flu virus is known to be going around and it is likely that a flulike illness has been caused by the flu virus.

Healthcare professionals should discuss the choice of oseltamivir or zanamivir with the person being offered the drugs. The decision should take into account which drug the person would prefer and any possible unwanted effects. If all else is equal, the cheapest drug should be used.

If there is an outbreak of ‘flu-like illness’ in a long-term residential or nursing home, oseltamivir and zanamivir may be offered to treat residents in ‘at-risk’ groups who have symptoms of flu. This could happen even if the flu virus is not around in the wider community outside the home, but the healthcare team should be sure that the illness is flu.

Amantadine is not recommended to treat people with flu.

Guidance replaces TA58 Flu treatment – zanamivir (review), amantadine and oseltamivir

Documents For healthcare professionals:

• TA168 Influenza – zanamivir, amantadine and oseltamivir (review): guidance (40p, 255.05 Kb)
• TA168 Influenza – zanamivir, amantadine and oseltamivir (review): guidance (MS Word format) (40p, 614 Kb)
• TA168 Influenza – zanamivir, amantadine and oseltamivir (review): quick reference guide (2p, 84.86 Kb)

Documents For patients, carers and the public:

• TA168 Influenza – zanamivir, amantadine and oseltamivir (review): understanding NICE guidance (4p, 48.89 Kb)
• TA168 Influenza – zanamivir, amantadine and oseltamivir (review): understanding NICE guidance (MS Word format) (4p, 510 Kb)

Implementing the Guidance:

• Influenza – zanamivir, amantadine and oseltamivir (review): audit support (MS Word format) (7p, 237 Kb)
• Influenza – zanamivir, amantadine and oseltamivir (review): costing statement (2p, 18.82 Kb)

Date of publication: January 2009

Publication type: Technology Appraisal

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Endovascular stent-grafts are recommended as a possible treatment for people with abdominal aortic aneurysms if:

• the aneurysm is below their kidney and has not burst,
• surgery is appropriate, and
• the person and their specialist have discussed the risks and benefits of this and other procedures and decided that endovascular stent–grafts are appropriate.

Aneurysm repair using endovascular stent–grafts should only be carried out in specialist centres by staff experienced in treating people with abdominal aortic aneurysms.

Endovascular stent–grafts are not recommended for people whose abdominal aortic aneurysm has burst unless they are taking part in research with the data collected in national databases to help improve patient care.

Documents For healthcare professionals:

• TA167 Abdominal aortic aneurysm – endovascular stent-grafts: guidance (43p, 278.21 Kb)
• TA167 Abdominal aortic aneurysm – endovascular stent-grafts: guidance (MS Word format)(43p, 645.5 Kb)
• TA167 Abdominal aortic aneurysm – endovascular stent-grafts: quick reference guide (2p, 66.73 Kb)

Documents For patients, carers and the public:

• TA167 Abdominal aortic aneurysm – endovascular stent-grafts: understanding NICE guidance(4p,  48.18 Kb)
• TA167 Abdominal aortic aneurysm – endovascular stent-grafts: understanding NICE guidance (MS Word format (4p, 507 Kb)

Implementing the Guidance:

• Abdominal aortic aneurysm – endovascular stent-grafts: audit support (MS Word format) (8p, 223 Kb)
• Abdominal aortic aneurysm – endovascular stent-grafts: costing statement (3p, 32.86 Kb)

Date of publication: January 2009

Publication type: Technology Appraisal

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on autologous blood injection for tendinopathy.  Tendonitis is the inflammation of the tendon – the fibrous tissue that connects muscles to bones – which may occur through overuse. In this treatment, blood is taken from the patient (which is sometimes treated in the laboratory) and then re-injected around the affected tendon to supply growth factors that initiate healing.

Documents:

• IPG279 Autologous blood injection for tendinopathy: guidance (2-p, 35.76 Kb)
• IPG279 Autologous blood injection for tendinopathy: understanding NICE guidance (4p, 55.16 Kb)
• IPG279 Autologous blood injection for tendinopathy: understanding NICE guidance (MS Word format) (4p, 406 Kb)
• IPG279 Autologous blood injection for tendinopathy: audit support (7p, 67.04 Kb)
• IPG279 Autologous blood injection for tendinopathy: consultation comments (4p, 34.35 Kb)
• Autologous blood injection for refractory tendonitis (interventional procedures overview) (18p, 103.92 Kb)
• Autologous blood injection for refractory tendonitis (interventional procedures consultation) (web page)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Title: Ultrasound-guided regional nerve block

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on ultrasound-guided regional nerve block. There are a number of conditions for which regional anaesthesia to allow surgery is required for a specific part of the body. This technique aims to provide accurate placement of local anaesthetic by using ultrasound guidance to position needles that deliver the local anaesthetic in the correct place next to the nerves.

Documents:

• Ultrasound-guided regional nerve block: guidance (2p, 35.27 Kb)
• Ultrasound-guided regional nerve block: understanding NICE guidance (4p, 55.79 Kb)
• Ultrasound-guided regional nerve block: understanding NICE guidance (MS Word format)(4p, 407 Kb)
• Ultrasound-guided regional nerve block: consultation comments (5p, 42.3 Kb)
• Ultrasound-guided regional nerve block (interventional procedures consultation)(web page)
• Ultrasound-guided regional nerve block (interventional procedures overview) (29p, 172.55 Kb)

Date of publication: January 2009

Publication type: Guidelance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on infracoccygeal sacropexy using mesh for vaginal vault prolapse repair. Uterine prolapse occurs when the womb (uterus) slips down from its normal position into the vagina. Infracoccygeal sacropexy is an operation that involves the insertion of a piece of material (mesh) with the aim of holding the womb in place.

Documents:

• IPG280 Infracoccygeal sacropexy using mesh for uterine prolapse repair: guidance (2p, 35.03 Kb)
• IPG280 Infracoccygeal sacropexy using mesh for uterine prolapse repair: understanding NICE guidance (4p, 55.41 Kb)
• IPG280 Infracoccygeal sacropexy using mesh for uterine prolapse repair: understanding NICE guidance (MS Word format) (4p, 408.5 Kb)
  
• IPG280 Infracoccygeal sacropexy using mesh for uterine prolapse repair: consultation comments (3p, 27.07 Kb)
• Infracoccygeal sacropexy using mesh for uterine prolapse repair: interventional procedure consultation document (web page)
• A systematic review of the efficacy and safety of using mesh or grafts in surgery for uterine or vaginal vault prolapse (231p, 9.06 Mb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: A cochlear implant in one ear is recommended as a possible option for everyone with severe to profound deafness if they do not get enough benefit from hearing aids after trying them for 3 months. Cochlear implants in both ears are recommended for the following groups with severe to profound deafness only if they do not get enough benefit from hearing aids after trying them for 3 months and the implants are placed during the same operation:

• children
• adults who are blind or have other disabilities which mean that they depend upon hearing sounds for spatial awareness.

An assessment should be carried out to find out if an implant would help before considering a cochlear implant. Any disabilities or difficulties in communicating, which might mean that the usual hearing tests are not suitable need to be taken into account. In such cases they should consider other methods for testing hearing. A later operation to place a cochlear implant in the second ear is only recommended for the following groups if they already had a cochlear implant in the other ear when the guidance was issued:

• children
• adults who are blind or have other disabilities which mean that they depend upon hearing sounds for spatial awareness.

In all cases, if more than one type of cochlear implant is suitable, the least expensive should be used. Costs should include the cost of the implant and the support package, and how reliable the system is. When an implant is placed in a second ear during the same operation the cost for the second implant should include currently available discounts on list prices of 40% or more.

Documents For healthcare professionals:

• TA166 Hearing impairment – cochlear implants: guidance (41p, 238.21 Kb)
• TA166 Hearing impairment – cochlear implants: guidance (MS Word format) (41p, 648.5 Kb)
  
• TA166 Hearing impairment – cochlear implants: quick reference guide (2p, 57.2 Kb)

Documents For patients, carers and the public:

• TA166 Hearing impairment – cochlear implants: understanding NICE guidance (4p, 61.47 Kb)
• TA166 Hearing impairment – cochlear implants: understanding NICE guidance (MS Word format) (4p, 503.5 Kb)

Implementing the Guidance:

• Hearing impairment – cochlear implants: audit support (9p, 240.5 Kb)
• Hearing impairment – cochlear implants: costing tool (Excel, 1.2 Mb 5)

Date of publication: January 2009

Publication type: Technology Appraisal

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Technology appraisal recommending the following techniques for storing kidneys from donors who have died:

• machine perfusion using the LifePort kidney transporter
• cold static storage using Belzer UW storage solution or Marshall’s hypertonic citrate solution.

The choice of storage method should be based on:

• the expertise and equipment available to the teams collecting the kidney
• how the teams are organised, and
• the distances involved.

If more than one of the storage methods are equally suitable the least costly should be used.

Documents For healthcare professionals:

• TA165 Organ preservation (renal) – machine perfusion and static storage: guidance (30p, 208.09 Kb)
• TA165 Organ preservation (renal) – machine perfusion and static storage: guidance (MS Word format) (30p, 603.5 Kb)
• TA165 Organ preservation (renal) – machine perfusion and static storage: quick reference guide (2p, 53.8 Kb)

Documents For patients, carers and the public:

• TA165 Organ preservation (renal) – machine perfusion and static storage: understanding NICE guidance (4p, 57.19 Kb)
• TA165 Organ preservation (renal) – machine perfusion and static storage: understanding NICE guidance (MS Word format) (4p, 502 Kb)

Implementation Guidance:

• Organ preservation (renal) – machine perfusion and static storage: audit support (4p, 160.5 Kb)
• Organ preservation (renal) – machine perfusion and static storage: costing statement (2p, 27.17 Kb)

Date of publication: January 2009

Publication type: Technology Appraisal

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:  This guidance is for all those who manage long-term (or recurring short- or long-term) sickness absence and incapacity, including employers and people working in the NHS. It will also be of interest to workplace representatives and trades unions, employees and those receiving incapacity benefit or employment and support allowance (ESA).

Three of the recommendations aim to help employers and employees work together to ensure the right support is available to help someone on sickness absence return to work as soon as they are able.

Recommendations for employers include:

• Identify someone who is suitably trained and impartial to undertake initial enquiries with an employee who is experiencing long-term sickness absence or recurring short- or long-term sickness absence.
• If necessary, arrange for a more detailed assessment by relevant specialist/s. This could be coordinated by a suitably trained case worker/s.
• Coordinate and support any health, occupational or rehabilitation interventions or services and any return-to-work plan agreed with the employee.

It also recommends that those who are unemployed and claiming incapacity benefit or ESA should be offered an integrated programme of support to help them enter or return to work. This advice is aimed at the Department for Work and Pensions and other relevant commissioning bodies and organisations.

Documents For healthcare professionals:

• PH19 Management of long-term sickness and incapacity for work: guidance (88p, 396.06 Kb)
• PH19 Management of long-term sickness and incapacity for work: guidance (MS Word format) (88p, 745 Kb)
• PH19 Management of long-term sickness and incapacity for work: quick reference guide (16p, 89.2 Kb)

Documents For patients, carers and the public:

• PH19 Management of long-term sickness and incapacity for work: quick reference guide (16p, 89.2 Kb)

Implementing the guidance:

• Management of long-term sickness and incapacity for work: checklist for managing absence (MS Word Format) (6p, 522.5 Kb)
• Management of long-term sickness and incapacity for work: slide set (Powerpoint, 310.5 Kb)
• Management of long-term sickness and incapacity for work: costing report (17p, 666 Kb)
• Management of long-term sickness and incapacity for work: business case (Excel, 110.5 Kb)

Background Information:

• New NICE guidance on helping people return to work following long term sickness absence (4p)
• PH19 Management of long-term sickness and incapacity for work: Fieldwork report (84p, 398.93 Kb)
• PH19 Management of long-term sickness and incapacity for work: Economic analysis report (76p, 497.62 Kb)
• PH19 Management of long-term sickness and incapacity for work: Evidence review 1 (380p, 2.09 Mb)
• PH19 Management of long-term sickness and incapacity for work: Evidence review 2 (199p, 1.1 Mb)
• PH19 Management of long-term sickness and incapacity for work: Evidence review 3 (106p, 617.11 Kb)
• PH19 Management of long-term sickness and incapacity for work: Additional evidence consultation report (41p, 363.12 Kb)
• PH19 Management of long-term sickness and incapacity for work: Mapping review (67p, 397.33 Kb)
• PH19 Management of long-term sickness and incapacity for work: Expert paper 1
• PH19 Management of long-term sickness and incapacity for work: Additional paper to support expert paper 1 (8p, 62.4 Kb)
• PH19 Management of long-term sickness and incapacity for work: Expert paper 2 (4p, 35.54 Kb)
• PH19 Management of long-term sickness and incapacity for work: Expert paper 3 (4p, 32.07 Kb)
• PH19 Management of long-term sickness and incapacity for work: Expert paper 4 (1p, 14.62 Kb)
• PH19 Management of long-term sickness and incapacity for work: Expert paper 5 (13p, 101.26 Kb)

Date of publication: March 2009

Publication type: Public Health Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Promotes the optimal provision of needle and syringe programmes (NSPs) among injecting drug users. It is for NHS and other professionals who have a direct or indirect role in, or responsibility for, NSPs. This includes those working in drug (and alcohol) action teams (DAATs), pharmacies, local authorities and the wider public, voluntary and community sectors. It may also be of interest to people who inject illicit substances and non-prescribed drugs, their families and other members of the public.

The recommendations relate to people over the age of 18 who inject illicit substances and non-prescribed anabolic steroids.

The guidance complements and supports, but does not replace, NICE guidance on drug and substance misuse.

Documents For healthcare professionals:

• PH18 Needle and syringe programmes: guidance (49p, 286.74 Kb)
  
• PH18 Needle and syringe programmes: guidance (MS Word format) (49p, 668 Kb)
• PH18 Needle and syringe programmes: quick reference guide (6p, 51.76 Kb)
  

Documents For patients, carers and the public:

PH18 Needle and syringe programmes: quick reference guide (6p, 51.76 Kb)

Implementing the Guidance:

• Needle and syringe programmes: costing template (Excel, 592.5 Kb)
  
• Needle and syringe programmes: costing statement (5p, 36.2 Kb)
• Needle and syringe programmes: presenter slides (Powerpoint, 2.64 Mb)
  

Background Information:

• New NICE guidance promotes benefits of needle and syringe programmes (3p)
  
• PH18 Needle and syringe programmes: economic modelling, revised full report October 2008 (93p, 509.52 Kb)
  
• PH18 Needle and syringe programmes: fieldwork report (92p, 514.56 Kb)
  
• PH18 Needle and syringe programmes: review of effectiveness and cost effectiveness, revised full report October 2008 (203p, 1.07 Mb)
• PH18 Needle and syringe programmes: review of qualitative evidence, revised full report August 2008 (159p, 1003.56 Kb)

Date of publication: January 2009

Publication type: Clinical Guideline

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:  Guidance is for those involved in promoting physical activity among children and young people, including parents and carers.

The NICE recommendations give advice on:

• how to promote the benefits of physical activity and encourage participation
• high level strategic planning
• the importance of consultation with children and young people and how to set about it
• planning and providing spaces, facilities and opportunities
• training people to run programmes and activities
• how to promote physically active travel such as cycling and walking.

Documents For healthcare professionals:

• PH17 Promoting physical activity for children and young people: guidance (89p, 400.13 Kb)
• PH17 Promoting physical activity for children and young people: guidance (MS Word format) (89p, 866.5 Kb)
• PH17 Promoting physical activity for children and young people: quick reference guide (24p, 528.13)

Documents For patients, carers and the public:

• PH17 Promoting physical activity for children and young people: quick reference guide (24p, 528.13 Kb)

Implementing the Guidance:

• Promoting physical activity for children and young people: costing statement (8p, 52.86 Kb)

Background Information:

• Promoting physical activity for children and young people: final fieldwork report (63p, 326.55 Kb)
• Promoting physical activity for children and young people: cost effectiveness anaylsis (35p, 239.13 Kb)
• Promoting physical activity for children and young people: epidemiology (94p, 453.46 Kb)
• Promoting physical activity for children and young people: quantitative correlates (51p, 310.24 Kb)
• Promoting physical activity for children and young people: qualitative correlates (110p, 368.2 Kb)
• Promoting physical activity for children and young people: interventions for under eights (59p, 306.07)
• Promoting physical activity for children and young people: active travel interventions (91p, 365.72 Kb)
• Promoting physical activity for children and young people: interventions for adolescent girls (75p, 412.47)
• Promoting physical activity for children and young people: family and community interventions (139p, 501.77 Kb)
• Promoting physical activity for children and young people: active play (92p, 453.99 Kb)
• Promoting physical activity for children and young people: economic evidence (52p, 571 Kb)

Date of publication: January 2009

Publication type: Public Health Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on photodynamic therapy for brain tumours. Photodynamic therapy (often abbreviated to PDT) has been developed as additional therapy (to enhance the effect of surgery) or as a treatment for tumours that are inoperable. Itinvolves giving the patient a drug that makes the tissue sensitive to light. A laser light source is used during the operation and in some cases for a few days afterwards to activate the light‑sensitive substance with the aim of destroying the tumour cells. Brain tumours may arise from brain tissue or spread from cancers in other parts of the body. Treatment usually consists of an operation to establish the nature of the tumour and, when possible, remove as much of it as seems safe.

Documents:

• IPG290 Photodynamic therapy for brain tumours: guidance (2p, 93.92 Kb)
• IPG290 Photodynamic therapy for brain tumours: understanding NICE guidance (8p, 60.06 Kb)
• IPG290 Photodynamic therapy for brain tumours: understanding NICE guidance (MS Word format) (8p, 409 Kb)
• IPG290 Photodynamic therapy for brain tumours: consultation comments (8p, 29.35 Kb)
• Overview of photodynamic therapy for brain tumours (20p, 118.68 Kb)
• Interventional procedures consultation document – photodynamic therapy for brain tumours (web page)

Date of publication: March 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: In percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation selected areas of the heart are destroyed using heat, with the aim of preventing the occurrence or conduction of abnormal electrical activity. The procedure is done through a special catheter which is inserted into the lower chest area and guided to the outside of the heart.  Ventricular tachycardia is a condition that affects the heart, causing an irregular pulse. It occurs when the electrical impulses controlling the heartbeat become disorganised, so that the heart beats too fast. When this happens, the heart cannot efficiently pump blood around the body. This may cause symptoms such as palpitations, chest pain or discomfort, shortness of breath, dizziness and fainting. Ventricular tachycardia increases the risk of cardiac arrest (when the heart stops beating). This is full guidance to the NHS in England, Wales, Scotland and Northern Ireland  from the National Institute for Health and Clinical Excellence (NICE) on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia.

Documents:

• IPG295 Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia: guidance (2p, 91 Kb)
• IPG295 Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia: understanding NICE guidance (4p, 50.29 Kb)
• IPG295 Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia: understanding NICE guidance (MS Word format) (4p, 406.5 Kb)
• Interventional procedures consultation document for percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia (web page)
• Overview of percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia (22p, 173.28 Kb)
  

Date of publication: March 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: In percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation, selected areas of the heart are destroyed using heat, with the aim of preventing the abnormal electrical impulses responsible for atrial fibrillation. The procedure is carried out through a special catheter which is inserted into the lower chest area and guided to the outer part of the heart.  Atrial fibrillation is a condition that affects the heart, causing an irregular heartbeat. It increases the risk of blood clots in the heart and stroke. Electrical impulses (originating from the atria, the small chambers of the heart) control the heartbeat. In atrial fibrillation these impulses become disorganised, so that the heart beats irregularly and too quickly. When this happens, the heart cannot efficiently pump blood around the body. This may cause symptoms such as palpitations, chest pain, shortness of breath, dizziness and fainting.  This is full guidance from the National Institute for Health and Clinical Excellence (NICE) to the NHS in England, Wales, Scotland and Northern Ireland on percutaneous (non-thracoscopic) epicardia catheter radiofrequency ablation for atrial fibrillation.

Documents:

• IPG294 Percutaneous (non-thoracoscopic) epicardial radiofrequency ablation for atrial fibrillation: guidance (2p, 90.66 Kb)
  
• IPG294 Percutaneous (non thoracoscopic) epicardial radiofrequency ablation for atrial fibrillation: understanding NICE guidance (4p, 50.16 Kb)
  
• IPG294 Percutaneous (non thoracoscopic) epicardial radiofrequency ablation for atrial fibrillation: understanding NICE guidance (MS Word format) (4p, 403.5 Kb)
• IPG294 Percutaneous (non thoracoscopic) epicardial radiofrequency ablation for atrial fibrillation: consultation comments (2p, 10.83 Kb)
• Overview of percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation (15p, 85.51 Kb)
• Interventional procedures consultation document – Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation (web page)
  

Date of publication: March 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Double vision (also known as diplopia) is seeing two images of a single object instead of one. In this procedure, the clear lens of one eye is removed and replaced with a non-transparent (opaque) lens. The aim is to block out one of the double images.  This is full guidance to the NHS in England, Wales, Scotland and Northern Ireland on implantation of an opaque intraocular lens for intractable double vision from the National Institute for Health and Clinical Excellence (NICE).

Documents:

• IPG293 Implantation of an opaque intraocular lens for intractable double vision: guidance (2p, 92.84 Kb)
• IPG293 Implantation of an opaque intraocular lens for intractable double vision: understanding NICE guidance (4p, 49.24 Kb)
• IPG293 Implantation of an opaque intraocular lens for intractable double vision: understanding NICE guidance (MS Word format) (4p, 406.5 Kb)
• IPG293 Implantation of an opaque intraocular lens for intractable double vision: understanding NICE guidance (large print format) (8p, 40.4 Kb)
• IPG293 Implantation of an opaque intraocular lens for intractable double vision: consultation comments (3p, 13.12 Kb)
• Interventional procedures consultation document – implantation of an opaque intraocular lens for intractable double vision (web page)
• Overview of implantation of an opaque intraocular lens for intractable double vision(15p, 53.85 Kb)

Date of publication: March 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny:   In patients with gastro-oesophageal reflux disease, the acidic contents of the stomach are able to travel backwards into the gullet, causing a burning sensation or pain (heartburn).  Full guidance from the National Institute for Health and Clinical Excellence (NICE) has been issued to the NHS in England, Wales, Scotland and Northern Ireland on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This endoscopic procedure uses electrically-generated heat to form a scar (radiofrequency ablation) in the lower end of the gullet with the aim of making it narrower, reducing the ability of the stomach contents to travel backwards (reflux).

Documents:

• IPG292 Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease: guidance (2p, 93.73 Kb)
• IPG292 Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease: consultation comments table (3p, 13.67 Kb)
• IPG292 Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease: understanding NICE guidance (4p, 50.44 Kb)
• IPG292 Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease: understanding NICE guidance (MS Word format) (4p, 408.5 Kb)
• Overview of endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (24p, 147.93 Kb)
• Interventional procedures consultation document – endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (web page)
• Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease: audit support (12p, 210.57 Kb)

Date of publication: March 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy.  Facial lipoatrophy (facial wasting) is a loss of fat underneath the skin, often on the face. It can occur as a side effect of antiretroviral drug treatment for HIV. Gel polymers are water-based, man-made substances that are injected under the skin to re-contour the depleted areas.

Documents:

• IPG291 Deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy: guidance (2p, 94.39 Kb)
• IPG291 Deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy: understanding NICE guidance (4p, 50.11 Kb)
• IPG291 Deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy: understanding NICE guidance (MS Word format) (4p, 409 Kb)
• IPG291 Deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy: audit support (MS Word fromat) (15p ,363 Kb)
• Interventional procedures consultation document – deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy (web page)
• Overview of deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy (20p, 112.75 Kb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on laparoscopic cystectomy replacing revious guidance on laparoscopic cystectomy (Interventional Procedures Guidance no. 26, December 2003).

This procedure is used to treat

• Invasive bladder carcinoma
• Ongoing incontinence due to paraplegia, where catheterisation results in infection and ongoing leakage
• Refractory complications in a defunctionalized bladder, where urinary diversion is already established

Laparoscopic cystectomy involves removing the bladder using small cuts (also known as ‘keyhole surgery’). In women, the bladder is removed through the wall of the vagina. In men, the bladder is removed with the prostate gland, through a small cut in the wall of the abdomen. The tubes that carry urine from the kidneys to the bladder (the ureters) may then be connected to a bag worn outside the body, or parts of the bowel can be used to make an artificial bladder which is drained by a connection to the abdomen wall or to the tube that carries urine out of the body (the urethra).

Documents:

• IPG287 Laparoscopic cystectomy: guidance (2p, 58.71 Kb)
• IPG287 Laparoscopic cystectomy: understanding NICE guidance (4p, 50.34 Kb)
• IPG287 Laparoscopic cystectomy: understanding NICE guidance (MS Word format) (4p, 409.5 Kb)
• IPG287 Laparoscopic cystectomy: consultation comments (4p, 43.46 Kb)
• Interventional procedures consultation document – laparoscopic cystectomy (web page)
• Overview of laparoscopic cystectomy (36p, 200.61 Kb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on intraocular lens insertion for correction of refractive error, with preservation of the natural lens.  Insertion of a clear plastic lens in front of the existing lens is a procedure that aims to improve vision in short-sightedness. Short-sightedness is the inability to see clearly at a distance. Eyesight can usually be corrected by wearing spectacles or contact lenses.

Documents:

• IPG289 Intraocular lens insertion for correction of refractive error, with preservation of the natural lens: guidance (2p, 58.3 Kb)
• IPG289 Intraocular lens insertion for correction of refractive error, with preservation of the natural lens: understanding NICE guidance (4p, 50.24 Kb)
• IPG289 Intraocular lens insertion for correction of refractive error, with preservation of the natural lens: understanding NICE guidance (MS Word format) (4p, 408.5 Kb)
• IPG289 Intraocular lens insertion for correction of refractive error, with preservation of the natural lens: understanding NICE guidance (large print format) (8p, 41.54 Kb)
• IPG289 Intraocular lens insertion for correction of refractive error, with preservation of the natural lens: consultation comments (4-, 29.97 Kb)
• Interventional procedures consultation document – intraocular lens insertion for correction of refractive error, with preservation of the natural lens (web page)
• Overview of intraocular lens insertion for correction of refractive error, with preservation of the natural lens (30p, 168.34 Kb)

Date of publication: February 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on extracorporeal photopheresis for Crohn’s disease. In extracorporeal photopheresis blood is removed from the patient, then the white blood cells are separated from the whole blood, treated with ultraviolet light and re-infused into the patient.  Crohn’s disease is a chronic inflammatory disease that affects the gastrointestinal tract. It is sometimes associated with other complications such as skin rashes and arthritis.

Documents:

• IPG288 Extracorporeal photopheresis for Crohn’s disease: guidance (2p, 55.99 Kb)
• IPG288 Extracorporeal photopheresis for Crohn’s disease: understanding NICE guidance (4p, 49.28 Kb)
• IPG288 Extracorporeal photopheresis for Crohn’s disease: understanding NICE guidance (MS Word format) (4p, 292.02 Kb)
• IPG288 Extracorporeal photopheresis for Crohn’s disease: consultation comments (5p, 34.74 Kb)
• Interventional procedures consultation document – extracorporeal photopheresis for Crohn’s disease (web page)
• Overview of extracorporeal photopheresis for Crohn’s disease (17p, 63.31 Kb)

Date of publication: February 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on functional electrical stimulation for drop foot of central neurological origin.  Drop foot is the inability to lift the foot and toes when walking. It can result from conditions such as stroke, multiple sclerosis or spinal cord injury. Functional electrical stimulation involves stimulation of the peripheral nerves that supply the paralysed muscle using electrodes that may be implanted or placed on the surface of the skin. The aim is to restore muscular function.

Documents:

• IPG278 Functional electrical stimulation for drop foot of central neurological origin: guidance (2p, 35.52 Kb)
• IPG278 Functional electrical stimulation for drop foot of central neurological origin: public information (4p, 55.87 Kb)
• IPG278 Functional electrical stimulation for drop foot of central neurological origin: public information (MS Word format) (4p, 404 Kb)
• IPG278 Functional electrical stimulation for drop foot of central neurological origin: consultation comments (33p,194.79 Kb)
• Functional electrical stimulation for drop foot of central neurological origin (interventional procedures consultation) (web page)
• Functional electrical stimulation for drop foot of central neurological origin (interventional procedures overview)(29p, 193.51 Kb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on infracoccygeal sacropexy using mesh for vaginal vault prolapse repair. Vaginal vault prolapse occurs in women with previous surgical removal of the womb when the upper vaginal wall slips down from its normal position down into the vaginal canal or outside of the vagina. Infracoccygeal sacropexy is an operation that involves the insertion of a piece of material (mesh) with the aim of holding the vaginal vault in place.

Documents:

• IPG281 Infracoccygeal sacropexy using mesh for vaginal vault prolapse repair: guidance (2p, 36.05 Kb)
• IPG281 Infracoccygeal sacropexy using mesh for vaginal vault prolapse repair: understanding NICE guidance (4p, 55.3 Kb)
• IPG281 Infracoccygeal sacropexy using mesh for vaginal vault prolapse repair: understanding NICE guidance (MS Word format) (4p, 410.5 Kb)
• IPG281 Infracoccygeal sacropexy using mesh for vaginal vault prolapse repair: consultation comments (2p, 23.28 Kb)
• Infracoccygeal sacropexy using mesh for vaginal vault prolapse repair: interventional procedure consultation document (web page)
• A systematic review of the efficacy and safety of using mesh or grafts in surgery for uterine or vaginal vault prolapse (231p, 9.06 Mb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on sacrocolpopexy with hysterectomy using mesh for uterine prolapse repair. Uterine prolapse occurs when the womb (uterus) slips down from its normal position into the vagina. Sacrocolpopexy is an operation involving the insertion of a piece of material (mesh) with the aim of holding the pelvic organs in place, following surgical removal of the womb.

Documents:

• IPG284 Sacrocolpopexy with hysterectomy using mesh for uterine prolapse repair: guidance (2p, 35.54 Kb)
• IPG284 Sacrocolpopexy with hysterectomy using mesh for uterine prolapse repair: understanding NICE guidance (4p, 56.27 Kb)
• IPG284 Sacrocolpopexy using mesh for uterine prolapse repair: understanding NICE guidance (MS Word format) (4p, 410.5 Kb)
• IPG284 Sacrocolpopexy with hysterectomy using mesh for uterine prolapse repair: consultation comments (2p, 23.66 Kb)
• Sacrocolpopexy using mesh for uterine prolapse repair: interventional procedure consultation document (web page)
• A systematic review of the efficacy and safety of using mesh or grafts in surgery for uterine or vaginal vault prolapse (231p, 9.06 Mb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on sacrocolpopexy using mesh for vaginal vault prolapse repair.  Vaginal vault prolapse occurs when organs above or around the vagina slip down from their normal position. Sacrocolpopexy is an operation that aims to provide support for the pelvic organs in their natural position. This is achieved by attaching a piece of material (mesh), usually from the top and back of the vagina, to a ligament of the lower back bone.

Documents:

• IPG283 Sacrocolpopexy using mesh for vaginal vault: guidance (2p, 36 Kb)
• IPG283 Sacrocolpopexy using mesh for vaginal vault: understanding NICE guidance (4p, 55.91 Kb)
• IPG283 Sacrocolpopexy using mesh for vaginal vault: understanding NICE guidance (MS Word format) (4p, 293.7 Kb)
• IPG283 Sacrocolpopexy using mesh for vaginal vault: comments table (5p, 35.19 Kb)
• Sacrocolpopexy using mesh for vaginal vault prolapse repair: interventional procedure consultation document (web page)
• A systematic review of the efficacy and safety of using mesh or grafts in surgery for uterine or vaginal vault prolapse (231p, 9.06 Mb)

Date of publication: January 2009

Publication type: Guidance

Acknowledgement: http://www.nice.org.uk

Source: NICE

The Skinny: Guidance to the NHS in England, Wales, Scotland and Northern Ireland on insertion of mesh uterine suspension sling (including sacrohysteropexy) for uterine prolapse repair.  Uterine prolapse occurs when the womb slips down from its normal position into the vagina. Uterine suspension sling involves an operation to insert a piece of material (mesh) with the aim of holding the womb in place.

Documents:

• IPG282 Insertion of mesh uterine suspension sling (including sacrohysteropexy) for uterine prolapse repair: guidance (2p, 35.73 Kb)
  
• IPG282 Insertion of mesh uterine suspension sling (including sacrohysteropexy) for uterine prolapse repair: understanding NICE guidance (4p, 54.46 Kb)
• IPG282 Insertion of mesh uterine suspension sling (including sacrohysteropexy) for uterine prolapse repair: understanding NICE guidance (MS Word format) (4p, 410 Kb)
• IPG282 Insertion of mesh uterine suspension sling (including sacrohysteropexy) for uterine prolapse repair: consultation comments (2p, 23.33 Kb)
• Insertion of mesh uterine suspension sling (including sacrohysteropexy) for uterine prolapse repair: interventional procedures consultation document (webpage)
  
• A systematic review of the efficacy and safety of using mesh or grafts in surgery for uterine or vaginal vault prolapse (231p, 9.06 Mb)

Date of publication: January 2009

Publication type: Guidelance

Acknowledgement: http://www.nice.org.uk